Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial - Summary - MDSpire

Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

  • By

  • Elizabeth A. R. Garfinkle

  • Renzo Perales-Linares

  • Ryan C. Gimple

  • Alexandra J. Livingstone

  • Kaleigh F. Roberts

  • Omar H. Butt

  • S. Peter Goedegebuure

  • Michael D. McLellan

  • Gue Su Chang

  • Jasreet Hundal

  • Jian Yan

  • Jaye B. Navarro

  • Sophia A. Paxton

  • Srestha Chattopadhyay

  • Neil Cooch

  • Alfredo Perales-Puchalt

  • Konstantina Stavroulaki

  • Sarah Rochestie

  • Joann Peters

  • Beth Junker

  • Jian L. Campian

  • Milan G. Chheda

  • Michael R. Chicoine

  • Albert H. Kim

  • Jon T. Willie

  • Gregory J. Zipfel

  • Joshua L. Dowling

  • Christopher A. Miller

  • Obi L. Griffith

  • Malachi Griffith

  • William E. Gillanders

  • Katherine E. Miller

  • Elaine R. Mardis

  • Niranjan Y. Sardesai

  • Gavin P. Dunn

  • Tanner M. Johanns

  • May 12, 2026

  • 0 min

Share

Objective:

To assess the safety, feasibility, and immunogenicity of a personalized neoantigen DNA vaccine platform in adult patients with newly diagnosed MGMT unmethylated glioblastoma, addressing the urgent need for new therapeutic options.

Key Findings:
  • Increased neoantigen identification by 45% through multi-sector sampling, highlighting the importance of comprehensive tumor analysis.
  • Median pre-vaccination tumor mutational burden was low at 2.6 mutations per megabase, indicating a challenge for immunotherapy.
  • Personalized DNA vaccines can accommodate a higher neoantigen payload compared to peptide vaccines, potentially improving treatment outcomes.
Interpretation:

The study demonstrates the potential of personalized neoantigen DNA vaccines to enhance immune responses in GBM patients with unmethylated MGMT, addressing the limitations of existing therapies and suggesting a new direction for treatment.

Limitations:
  • Small sample size of nine patients limits generalizability and may introduce selection bias.
  • Short follow-up period may not capture long-term efficacy and safety, necessitating further studies.
Conclusion:

Personalized neoantigen DNA vaccination shows promise as a novel therapeutic approach for MGMT unmethylated glioblastoma, warranting further investigation in larger trials to validate these findings.

Original Source(s)

Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

  • by Elizabeth A. R. Garfinkle, Renzo Perales-Linares, Ryan C. Gimple, Alexandra J. Livingstone, Kaleigh F. Roberts, Omar H. Butt, S. Peter Goedegebuure, Michael D. McLellan, Gue Su Chang, Jasreet Hundal, Jian Yan, Jaye B. Navarro, Sophia A. Paxton, Srestha Chattopadhyay, Neil Cooch, Alfredo Perales-Puchalt, Konstantina Stavroulaki, Sarah Rochestie, Joann Peters, Beth Junker, Jian L. Campian, Milan G. Chheda, Michael R. Chicoine, Albert H. Kim, Jon T. Willie, Gregory J. Zipfel, Joshua L. Dowling, Christopher A. Miller, Obi L. Griffith, Malachi Griffith, William E. Gillanders, Katherine E. Miller, Elaine R. Mardis, Niranjan Y. Sardesai, Gavin P. Dunn, Tanner M. Johanns

  • May 12, 2026

Related Content

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy